Business
Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center
Preclinical data demonstrate potent single-agent and combination effects in head and neck squamous cell carcinoma (HNSCC) models, including synergy with anti–PD-1 therapy Initial Phase 1 clinical update shows early disease control in first HPV+ patient treated with APR-1051 DOYLESTOWN, Pa., June 25, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer
About this update from Aprea Therapeutics, Inc.
[{"type":"image","alt":"Aprea Therapeutics","displaySize":"","headline":null,"caption":"Aprea Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":73,"url":"https://media.zenfs.com/en/globenewswire.com/99b3e900fb935fcf64456ae36360cec0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bNZPaglg_h8I4EDLnMTyIg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/99b3e900fb935fcf64456ae36360cec0","width":300,"height":73}},"lazy":false},{"type":"text","content":"Preclinical data demonstrate potent single-agent and combination effects in head and neck squamous cell carcinoma (HNSCC) models, including synergy with anti–PD-1 therapy","length":170,"tagName":"p"},{"type":"text","content":"Initial Phase 1 clinical update shows early disease control in first HPV+ patient treated with APR-1051","length":103,"tagName":"p"},{"type":"text","content":"DOYLESTOWN, Pa., June 25, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today announced new preclinical data and a clinical update on APR-1051, the Company’s next-generation oral WEE1 inhibitor, in human papillomavirus–positive (HPV+) head and neck squamous cell carcinoma (HNSCC).","length":507,"tagName":"p"},{"type":"text","content":"These findings result from an ongoing translational research collaboration with renowned oncology leader MD Anderson Cancer Center and support the potential of APR-1051 both as a single agent and in rational immunotherapy combinations for biomarker-driven treatment of HPV+ HNSCC. “We are excited by the preclinical data generated by independent researchers, and the early clinical signal of APR-1051 in an HPV-positive cancer patient,” said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea Therapeutics. “We believe that APR-1051 could offer significant differentiation in the competitive oncology landscape, as a single agent, as well as in combination with checkpoint inhibitors.”","length":700,"tagName":"p"},{"type":"text","content":"Preclinical Highlights from MD Anderson Collaboration:","length":54,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":...